HUGE HEADCOUNT REDUCTIONS

Discussion in 'Genentech' started by anonymous, Aug 28, 2017 at 1:17 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    How much did GNE pay ZS for this incompetence? Did anyone read the surveys from last spring? The whole process is demoralizing. Some really top CSs were displaced, territories reassigned to people who've never covered them, crazy geographies, outrageous favoritism, and no criteria given to those who are ineligible for the streamlined selection. Double secret? Looks like a possible lawsuit. Leadership, HR, and legal needs to wake up. Actions have consequences.
     

  2. anonymous

    anonymous Guest

    Don’t be foolish with as many lawyers as there are in this organization and as much power as legal wields, they’ve made certain it’s all legal. That’s why much of it makes no sense, the criteria had to be very vanilla and not take into account many observable factors that could create perceptions of bias.

    Just because the criteria weren’t clearly spelled out or disclosed doesn’t mean they were inconsistent. On the contrary, they are hard and fast, allowing for no exceptions to avoid the potential for legal consequences.

    I feel bad for those displaced, just like CIP a few years ago, but the best approach is to take the severance and move on. View it as an opportunity for growth, personally and professionally. Dealing with and overcoming adversity is a very admirable character trait and the confidence it instills in a person makes them attractive to future employers.
     
  3. anonymous

    anonymous Guest

    I don't know why people are complaining...we got rid of A LOT of shitty reps and pretenders. And those that are still here should be thankful that you still have a job- the industry is changing big time and will continue to change. You could easily make an argument that they could have gotten ridden of A LOT more reps as the majority of us aren't needed. We make great money and have great benefits. The people that got the snip should be fine- lots of jobs in the industry for performers and lots of jobs outside of the industry for the pretenders!

    Relax and stop blaming ZS associates- we all know it could have/ should have been much much worse.
     
  4. anonymous

    anonymous Guest

    you know what Emeril always says......
     
  5. anonymous

    anonymous Guest

    The Avastin reps should of all been shit-canned! They suck tripping over eachother trying to get a lunch! Biosimilars are coming....They are next!!!!

    Hope some of the incompetent Sr. Mgt got fired! They created the problems. They sell nothing and bring no money in to Genentech.
     
  6. anonymous

    anonymous Guest

    Yes, biosimilars are on the horizon, but $2B in annual sales with a promotion sensitive product warrants keeping a couple hundred reps until biosims actually make a significant impact on sales, and they will. Plenty of medical groups out there who can hardly wait to bend GNE over and drive it deep with no KY.
     
  7. anonymous

    anonymous Guest

    Is this why there are no sales jobs posted on the G career site ?
     
  8. anonymous

    anonymous Guest

    Survival of the ass kissers.

    You do not sell or see your customers. Give credit to MRK and BMS for kicking your ass!!!

    Look at what competition has done to your products. GNY It's like working at IBM or GE back in they day. Follow those stocks lately???

    Do you even know when business quarters start or end or what your product revenue running rate is to make quota. You do not. But you look good to your director and know how to order Starbucks.

    You get you ass kicked by competitors without Ivy League educations. They are hard working and street smart. They smell weakness and lazy work ethic.

    Hang on as long as you can and enjoy the ride while it lasts and prepare for a difficult landing.
     
  9. anonymous

    anonymous Guest

    You are right, our marketing does not know how to compete. They have had their heads handed to them by Meek and BMS. We are so far behind them and we can't catch up. We will always be 3rd to market on the big indications. Oncology is not going to get any better, start looking now.
     
  10. anonymous

    anonymous Guest

    third to market because Sandra thinks she does science, instead of bringing drugs to market asap

    Genentech arrogance at play
     
  11. anonymous

    anonymous Guest

    At least from a Vacaville contract worker point of view, this is definitely a turning point.

    Genentech treats contract workers like garbage but expects the same work as if they're blue badge. I was hired on as an E3 contractor that constantly participated in and managed projects with people that were surprised that I was green.

    Come to 11/01 and they lay off 130 blue badge positions with pay for two months and a year severance. What do green badges get? Nothing.

    They keep people around that are entitled garbage who think they're invulnerable to cuts and are riding those laurels as if biosimilars are some figment of their imagination.

    Wake up, blue is the new green.
     
  12. anonymous

    anonymous Guest

     
  13. anonymous

    anonymous Guest

    ZS does this in every company. A complete disaster of a process managed by incompetent junior people who don't have a clue about geography or workload.
     
  14. anonymous

    anonymous Guest

     
  15. anonymous

    anonymous Guest

    FRM's are the least accountable group and yet seem unfazed by changes. If the CS's had the additional FRM responsibility, they'd actually add more value to a practice and differentiate the company from others.Don't give me the BS that the comp plan would have to change. Conveying info on coding and how to access Access Solutions should be an instrumental part of the CS role. Retina FRM's may be the least accountable group out there, half are purely reactive to customer issues and only get out of the house when they have something new to discuss with an office
     
  16. anonymous

    anonymous Guest

    Definitely agree! In years past CSs took the role of FRMs and were seen as valued consultants to accounts both clinically and in the reimbursement arena. The compliance barrier is BS...HIPPA existed then and no problems. There are ways to make it work and isn't GNE looking for a broader role for the CSs with greater efficiencies? Time to break down the silos and revert to some retro thinking.
     
  17. anonymous

    anonymous Guest

    Hey Bill A, you listening here? Time to listen to your field personnel and not the BU VPs, nor the franchise heads. We are the face of the company with those we serve, please give us some credit for understanding the needs of our customers. I’m about ready to go elsewhere for an opportunity with a company that gets it, this entitlement with non revenue generating field personnel has gone on for too long.
    Before there were FRM’s and FPM’s, the CS’s did it all and the job got done the right way.......
     
  18. anonymous

    anonymous Guest

    Well-said and so true! Unfortunately, we'll continue to lose good people if our skills aren't put to use. I'm looking to leave in the near future after a long career at GNE. Just can't take the entitlement, Big Pharma micro-management, delicate egos and, don't kid yourself, putting the patients last.

    Face it, GNE is now fully Roche and it's heading down the same loser trail they blazed. They finally killed the goose that laid the golden egg. Just glad I'll be somewhere else. A real shame.
     
  19. anonymous

    anonymous Guest

    Yes and having more ancillary roles is a complete joke. Reps helped BAMs, RGMs, BFRMs and everyone else who do not produce revenue, through the gatekeepers of all of the offices. Then the same BAMS etc take credit for all that has happened. Oh and the interviews for these? HR should look at that one.
    We all know what really happened.
     
  20. anonymous

    anonymous Guest

    You were right about everything. Any on going advise for the rest of us? Where are you now?